• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    FDA Confirms Paragraph IV Patent Litigation for Beclomethasone Dipropionate Inhalation Aerosol

    FDA

    Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment

    PHARMAFILE

    NHS Scotland recommends Chiesi’s Trimbow for asthma

    PHARMAFILE

    Pts Packers And Providers is on FDA Import Alert List

    FDA

    FDA Confirms Paragraph IV Patent Challenge of Qvar 20911 (Beclomethasone Dipropionate) 40 mcg/actuation and 80 mcg/actuation

    FDA

    Class 3 FMD Medicines Recall

    PSNC

    NPPA fixes retail prices of 22 formulations under DPCO, 2013

    PHARMABIZ

    Determination That QVAR 40 and QVAR 80 Beclomethasone Dipropionate HFA

    FEDERALREGISTER

    Chiesi Farmaceutici`s Riarify (beclometasone;formoterol;glycopyrronium bromide) Receives Approval In Europe

    EMA

    Five new medicines backed for EU approval

    PHARMA TIMES

    EMA’s CHMP Recommends Five New Medicines for Approval

    RAPS

    Five medicines recommended for approval, including two orphans

    EMA

    Chiesi Farmaceutici`s Trimbow (beclometasone / formoterol / glycopyrronium bromide) Receives Approval In Europe

    EMA

    EU nod for Chiesi’s COPD therapy

    PHARMA TIMES

    Dispersibility of lactose fines as compared to API in dry powders for inhalation

    PHARMA-EXCIPIENTS

    Anvisa approves novel medicines for asthma, hypertension and brain tumor

    ANVISA

    Teva Pharmaceuticals USA initiates Class III recall of Beclomethasone Dipropionate

    FDA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.